Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) priced its initial public offering in Hong Kong at the upper limit of its indicative range to raise HK$9.75 billion in net proceeds.
The Chinese drugmaker issued 224.5 million shares at HK$44.05 each, the top end of its guidance of as low as HK$41.45 per share, according to a Thursday filing with the Hong Kong Exchange.
The deal's Hong Kong public offering portion was 454.9 times subscribed, prompting the company to issue 48.3 million shares, a near fourfold increase from the 12.3 million shares initially allotted.
The international offering portion was 17.1 times subscribed, and the firm issued 176.2 million shares, lower than the initial allocation of 212.2 million.
The cornerstone investors, including Singaporean sovereign wealth fund GIC, subscribed to a total of 93.7 million IPO shares.
Hengrui Pharma starts trading on the Hong Kong bourse today, May 23.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。